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B cells expressing potent and broadly neutralizing antibodies to HIV-1 have been found in many
infected individuals, suggesting that adaptive immunity has the capacity to defeat viral escape.
Gao et al. uncover an intermediate stage in this process when viral escape from one ‘‘helper’’
B cell lineage selects variants that drive a separate B cell lineage toward broad neutralization.Understanding the natural course of any
infection and the emergence of adaptive
immunity promises clues to the design of
prophylactic vaccines. While the progres-
sive course of HIV-1 infection is relentless,
analyses of HIV-1 specific adaptive im-
munity have been highly informative (Corti
and Lanzavecchia, 2013). In this issue of
Cell, Gao et al. (2014) move a step further
toward understanding the dynamic inter-
play between viral evolution and adaptive
immune response. The HIV-1 envelope
spike (Env) facilitates virus entry into
host cells and is the focus of much of
this immune activity (West et al., 2014).
However, initial waves of adaptive
immunity and the early production of
neutralizing antibodies is rapidly defeated
through viral escape. Founder viruses that
express mutant versions of the original
immune targets overtake infection and
escape neutralization (Burton et al.,
2012). Nevertheless, after many years of
persistent infection, some individuals
contain memory B cells that express
Env-specific antibodies able to neutralize
variants of the original ‘‘autologous’’ virus.
Importantly, these antibodies also display
potent and broad cross-reactivity to
‘‘heterologous’’ virus never seen by the
host (West et al., 2014). How these
broadly neutralizing antibodies (bnAbs)
develop in infected individuals remains a
central issue for the field.
The existence of Env-specific bnAbs
suggests that the adaptive immune
response can potentially defeat viral
escape. Elegant longitudinal studies of a
single infected individual recently map-
ped the structural changes that accom-
pany dynamic coevolution of bnAbs and
viral escape mutants (Liao et al., 2013).
These studies revealed the presence ofa mature CH103 B cell lineage that ex-
pressed bnAbs recognizing the D loop of
the CD4 binding site (CD4bs) in HIV-1
Env. The ongoing evolutionary tension
between virus escape and neutralizing
antibody production was clearly evident
early in this donor (CH505) and extended
for years after initial infection. BnAb activ-
ity could be seen in highly mutated and
clonally related members of this CH103
B cell lineage. Predicted intermediate
precursors in this lineage could be con-
structed with capacity to neutralize auto-
logous variants without bnAb function.
Now Gao et al. (Gao et al., 2014) delve
more deeply into the mechanisms under-
lying this evolutionary interplay between
virus andmemory B cells in donor CH505.
Extensive in vitro reactivation of
memory B cells from peripheral blood
at earlier stages of infection revealed
low frequencies of Env-specific B cells
belonging to the CH103 lineage with
fewer mutations and lower broad cross-
reactivity as predicted. Extensive screen-
ing for 124 different pseudovirus variant
reactivities reveals that one of the contact
sites for the CH103 lineage, the D loop
of the CD4bs, contains mutations that
enhance binding to the variant Env. This
key observation indicates that CH103
lineage reactivity could not have selected
the variant expressing the D loop mutant
needed for bnAbs reactivity.
Based on this surprising enhanced
reactivity, Gao et al. screen antibodies
from large numbers of memory B cell
cultures for the non-CH103 lineage that
can neutralize founder virus but not
D loop mutants. One out of another 150
clonal lineages has this property and at
similar frequencies to the intermediate
versions of the CH103 lineage. MultipleCellmembers of this new CH235 lineage
have clearly contrasting reactivity pat-
terns to its CH103 bnAb counterpart
that eventually promoted complete viral
escape. Knowing the structural dynamics
of viral escape and the recognition bias of
the CH103 bnAbs in this individual, the
authors propose that the CH235 lineage
drove selection of the D loop mutant
needed for maturation of bnAb reactivity
(Figure 1). Hence, cooperation between
separate B cell lineages underlies gradual
acquisition of bnAb reactivity.
While individuals expressing bnAbs
do not eradicate infection, these potent
antibodies can be effective under condi-
tions of passive transfer. Recent studies
in humanized mouse models and
macaques demonstrate the efficacy of
combinations of bnAbs to block initial
disease and suppressing ongoing infec-
tion (Barouch et al., 2013). Unfortunately,
the predicted germ-line ancestors of
these highly-mutated bnAbs rarely bind
the founder Env. This conundrum leads
to new vaccine strategies that modify
initial immunogens to recruit unmutated
ancestors coupled to boost regimes using
HIV-1 variant antigens (Jardine et al.,
2013). Based on the current studies
(Gao et al., 2014), it is possible that the
initial desirable ‘‘helper’’ lineages are
quite distinct from those that will eventu-
ally drive broad neutralization. It is equally
plausible that variant immunogens may
serve to bypass these early steps in the
development of bnAbs.
All proposed mechanisms of bnAb
development depend on the ongoing
capacity of Env-specific memory B cells
to respond to viral escape. At early stages
of infection, viral escape is followed by
altered patterns of antibody recognition158, July 31, 2014 ª2014 Elsevier Inc. 475
Figure 1. Cooperative Mechanism for the Development of Broadly Neutralizing Antibodies
during HIV-1 Infection
Infection of individual donor CH505 with the founder virus expressing the original HIV-1 Envelope protein
stimulates the production of neutralizing antibodies toward multiple sites on this critical surface receptor.
These blocking antibodies will inhibit survival and replication of the original viruses but permit and promote
the expansion of viral variants expressing mutant versions of the original Env protein. Multiple rounds of
viral escape and initial neutralization can be monitored in this individual. By week 41 in this individual,
multiple members of two separate B cell lineages, CH103 (IA3, IA4, 105) and CH235 (235, 240, 241) are
detected with distinct reactivity patterns across a wide spectrum of variant Env proteins. Importantly,
CH235 drives complete viral escape across multiple Env epitopes. However, in doing so this CH235
response selects Env variants containing mutations in the D loop of the CD4bs. These D loop mutants
display enhanced binding to the CH103 lineagemembers to provide the antigenic drive towardmaturation
and broadly neutralizing antibody (bnAb) reactivity. In this manner, the two memory B cell lineages
cooperate in the development of HIV-1 Env-specific bnAbs.and neutralization of initial escapees (Liao
et al., 2013). Eventual maturation of an
effective memory B cell lineage toward
broad neutralization must also be actively
driven by variant antigen (Gao et al.,
2014). This dynamic evolution in memory
B cell specificity occurs within secondary
lymphoid tissues in specialized microen-476 Cell 158, July 31, 2014 ª2014 Elsevier Invironments called germinal centers (GC)
(McHeyzer-Williams et al., 2012; Victora
and Nussenzweig, 2012). How these
variant antigens drive some GC B cells
to evolve Env-specific bnAb remains a
central practical issue for vaccine design.
Promoting effective B cell memory
(Tarlinton and Good-Jacobson, 2013)c.and the development of bnAb specificities
remains a central challenge to field. The
studies by Gao et al. propose a new
sequential mechanism that drives the
gradual development of these vital bnAb
specificities and promises to inform
immunogen design for the next gene-
ration of HIV-1 vaccines.REFERENCES
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